Compounded Retatrutide

Triple-receptor agonist — investigational. Phase 2 data only.

Overview

Retatrutide is an investigational triple-receptor agonist targeting GIP, GLP-1, and glucagon receptors. It has completed Phase 2 trials but is not FDA-approved in any form. Compounded retatrutide is not the same as any approved medication. Phase 2 NEJM data showed notable effects on body weight in the studied population. Phase 3 data is not yet available.

Mechanism

Adding glucagon receptor agonism introduces additional effects on energy expenditure and hepatic glucose output. Long-term safety profile has not been established.

Clinical Considerations

• Available only where prior GLP-1 or dual GIP/GLP-1 therapy has been clinically insufficient.
• Not FDA-approved in any form. Phase 3 trials ongoing as of this writing.
• MTC/MEN2 contraindication applies. Requires provider evaluation.

Potential Side Effects

• GI effects (nausea, reduced appetite, diarrhea) — expected given triple-receptor mechanism.
• Injection site reactions.
• Long-term safety profile not yet established — Phase 3 data is not yet available.
• Same MTC/MEN2 contraindication applies as other GLP-1 class agents.

All prescriptions require a telehealth consultation with a licensed provider. A prescription is not guaranteed. Individual results vary. Not FDA-approved unless noted otherwise.